SDC1 and plasma cell myeloma: Venkata and collaborators recently showed that SphK2 represents a potential therapeutic target for the treatment of MM by using ABC294640, a SphK2-specific inhibitor that exhibited anti-myeloma activity in primary human CD138+ cells and in in vivo mouse xenograft models.